Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine investigator-assessed progression-free survival (invPFS) by RECIST Version 1.1 for rucaparib versus chemotherapy.
Critère d'inclusion
- Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer